Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | BCHE | P06276 | 4/20 | 0.38 |
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.37 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 5/20 | 0.37 |
| ▸ | THRA | P10827 | 4/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27902001 | 0.80 | KEAP1 (0.39) | BCHEACHEKDM4EMAPTSAE1 | |
| SCHEMBL3601655 | 0.80 | THRB (0.51) | BCHEACHEKDM4ETHRBTHRA | |
| SCHEMBL27639101 | 0.79 | CFD (0.40) | BCHEACHEKDM4EMAPTSAE1 | |
| SCHEMBL3600323 | 0.78 | BCHE (0.43) | BCHEACHETHRBTHRA | |
| SCHEMBL3593921 | 0.78 | PPARA (0.45) | PPARATHRBTHRAPPARG | |
| SCHEMBL27639102 | 0.77 | BCHE (0.37) | BCHEACHEKDM4EMAPTSAE1 | |
| SCHEMBL3598090 | 0.77 | BCHE (0.45) | BCHEACHEKDM4ETHRBTHRA | |
| SCHEMBL3594435 | 0.77 | SLC5A1 (0.42) | BCHEACHE | |
| SCHEMBL27639121 | 0.77 | ALOX15 (0.39) | BCHEACHEKDM4EMAPTSAE1 | |
| SCHEMBL27639120 | 0.77 | ADRB3 (0.46) | BCHEACHETHRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465815-B2 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20070099990-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099990-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | SMN1; SMN2 4180/4885PPARA 490/4885BCHE 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.